Elequin Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Elequin Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-24	Closed	–	–	732
2022 Q2	$0	Sell	24 -7	-23%	-$49	﹤0.01%	460
2022 Q1	$0	Buy	+31	New	+$239	﹤0.01%	352

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Elequin Capital's AERI Position: Q3 2022 in Review

Elequin Capital sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 24 shares.

Elequin Capital first reported a position in AERI in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

Elequin Capital reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Elequin Capital sold 24 Aerie Pharmaceuticals shares in Q3 2022.
Elequin Capital first reported a position in Aerie Pharmaceuticals in Q1 2022 and held it in 2 quarters.
Elequin Capital's Aerie Pharmaceuticals position peaked at $0 in Q2 2022.
156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Elequin Capital's 13F filing for Q3 2022, filed 10 Nov 2022.